EPM July/August 2017

Editor's desk — with increasing antibiotic resistant bacteria will we see the tide turn for R&D efficiency?

Analysis — how to succeed in pharma outsourcing and accelerate innovation in healthcare.

Opinion — looking at the questions arising in the pharma community as a result of the political uncertainty.

Regulatory affairs — discussing how marketing authorisation can be supported with non-clinical overviews and the effect Brexit will have on pharmacovigilance.

Cover story — Natoli reveals anticipatory experiments that can help make the transition from R&D to full-scale as smooth as possible.

Clinical trials — step-by-step guide to fund lower priority trials, how collaborations can speed up trials, the challenge of monitoring adherence and how a new EU regulation will affect early phase clinical trials.